Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TDI 01 - Beijing Tide Pharmaceutical/Graviton

Next Previous
X
Search
Drug Profile

TDI 01 - Beijing Tide Pharmaceutical/Graviton

Alternative Names: TDI-01

Latest Information Update: 21 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Tide Pharmaceutical
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Neuroprotectants; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease
  • Preclinical Cancer; CNS disorders; Idiopathic pulmonary fibrosis; Viral infections
  • No development reported Non-alcoholic steatohepatitis; Pulmonary fibrosis

Most Recent Events

  • 06 Feb 2024 Phase-I/II clinical trials in Graft-versus-host disease (Treatment-experienced) in China (PO) (NCT06169722)
  • 13 Dec 2023 Beijing Tide Pharmaceuticals plans a phase Ib/II trial for Graft versus host disease (Treatment-experienced) in China (PO)(NCT06169722)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top